Earnings In Brief
Boston Scientific stent sales reflect growing competition: Boston Scientific's drug-eluting coronary stent sales totaled $428 million in the first quarter, an 8.5% decline from the prior-year period and a 1.6% sequential decrease from the fourth quarter of 2007, the firm reported April 21. The drop was due in part to price cuts and increased competition in the U.S. with the launch in February of Medtronic's Endeavor zotarolimus-eluting stent. Wachovia analyst Larry Biegelsen estimates that Boston Scientific's Taxus paclitaxel-eluting stent ceded four points of U.S. market share to Endeavor during the quarter versus seven points for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent. Boston Scientific estimates that Endeavor held U.S. share of 12%-13% at the end of the quarter. Despite the market share shift, Chief Operating Officer Paul LaViolette pointed to "clear evidence of recovery" in the drug-eluting stent market. The firm's cardiac rhythm management sales of $565 million in Q1 reflect a 4.8% year-over-year advance
More from Archive
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.
St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.
Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.
More from Medtech Insight
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.





